SW43

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563109

CAS#: 1421931-15-8

Description: SW43 is a sigma-2 receptor selective ligand.

Chemical Structure

img
SW43
CAS# 1421931-15-8
Instruction

Theoretical Analysis

MedKoo Cat#: 563109
Name: SW43
CAS#: 1421931-15-8
Chemical Formula: C27H45N3O4
Exact Mass: 475.34
Molecular Weight: 475.670
Elemental Analysis: C, 68.18; H, 9.54; N, 8.83; O, 13.45

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: SW43; SW-43; SW 43;

IUPAC/Chemical Name: (2,5-Dimethoxy-phenyl)-carbamic acid 9-(10-amino-decyl)-9-aza-bicyclo[3.3.1]non-3-yl ester

InChi Key: CJQNACPQMWELAS-UHFFFAOYSA-N

InChi Code: InChI=1S/C27H45N3O4/c1-32-23-14-15-26(33-2)25(20-23)29-27(31)34-24-18-21-12-11-13-22(19-24)30(21)17-10-8-6-4-3-5-7-9-16-28/h14-15,20-22,24H,3-13,16-19,28H2,1-2H3,(H,29,31)

SMILES Code: O=C(OC1CC(N2CCCCCCCCCCN)CCCC2C1)NC3=CC(OC)=CC=C3OC

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 475.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Ludwig JM, Xing M, Gai Y, Sun L, Zeng D, Kim HS. Targeted Yttrium 89-Doxorubicin Drug-Eluting Bead-A Safety and Feasibility Pilot Study in a Rabbit Liver Cancer Model. Mol Pharm. 2017 Aug 7;14(8):2824-2830. doi: 10.1021/acs.molpharmaceut.7b00336. Epub 2017 Jul 25. PubMed PMID: 28700244.

2: McDonald ES, Mankoff J, Makvandi M, Chu W, Chu Y, Mach RH, Zeng C. Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells. Biochem Biophys Res Commun. 2017 May 6;486(3):788-795. doi: 10.1016/j.bbrc.2017.03.122. Epub 2017 Mar 24. PubMed PMID: 28347815.

3: Ludwig JM, Gai Y, Sun L, Xiang G, Zeng D, Kim HS. SW43-DOX ± loading onto drug-eluting bead, a potential new targeted drug delivery platform for systemic and locoregional cancer treatment - An in vitro evaluation. Mol Oncol. 2016 Aug;10(7):1133-45. doi: 10.1016/j.molonc.2016.05.003. Epub 2016 May 21. PubMed PMID: 27262893; PubMed Central PMCID: PMC4972658.

4: Hashim YM, Spitzer D, Vangveravong S, Hornick MC, Garg G, Hornick JR, Goedegebuure P, Mach RH, Hawkins WG. Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. Mol Oncol. 2014 Jul;8(5):956-67. doi: 10.1016/j.molonc.2014.03.005. Epub 2014 Mar 26. PubMed PMID: 24731702; PubMed Central PMCID: PMC4082741.

5: Garg G, Vangveravong S, Zeng C, Collins L, Hornick M, Hashim Y, Piwnica-Worms D, Powell MA, Mutch DG, Mach RH, Hawkins WG, Spitzer D. Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer. Mol Cancer. 2014 Mar 7;13:50. doi: 10.1186/1476-4598-13-50. PubMed PMID: 24602489; PubMed Central PMCID: PMC4015918.

6: Hornick JR, Vangveravong S, Spitzer D, Abate C, Berardi F, Goedegebuure P, Mach RH, Hawkins WG. Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer. J Exp Clin Cancer Res. 2012 May 2;31:41. doi: 10.1186/1756-9966-31-41. PubMed PMID: 22551149; PubMed Central PMCID: PMC3414770.

7: Hornick JR, Xu J, Vangveravong S, Tu Z, Mitchem JB, Spitzer D, Goedegebuure P, Mach RH, Hawkins WG. The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. Mol Cancer. 2010 Nov 22;9:298. doi: 10.1186/1476-4598-9-298. PubMed PMID: 21092190; PubMed Central PMCID: PMC3106998.